You are required ID and Password when you access full texts.
Vol.68 No.S-1 November 2020
An overview of oral lascufloxacin, a novel quinolone antibiotic
Jpn. J. Chemother. 68 (S-1): 1-15, 2020
Pharmacokinetics of lascufloxacin in patients with renal dysfunction
Jpn. J. Chemother. 68 (S-1): 16-23, 2020
Pharmacokinetics of lascufloxacin in patients with hepatic impairment
Jpn. J. Chemother. 68 (S-1): 24-31, 2020
Effect of lascufloxacin on the plasma concentrations of theophylline in healthy volunteers
Jpn. J. Chemother. 68 (S-1): 32-40, 2020
Phase III double-blind comparative study of lascufloxacin versus levofloxacin in patients with community-acquired pneumonia
Jpn. J. Chemother. 68 (S-1): 41-54, 2020
Open-label study of lascufloxacin for secondary infections in patients with chronic pulmonary diseases and patients with acute bronchitis
Jpn. J. Chemother. 68 (S-1): 55-67, 2020
Phase III double-blind comparative study of lascufloxacin versus levofloxacin in patients with sinusitis
Jpn. J. Chemother. 68 (S-1): 68-80, 2020
Open-label study of lascufloxacin in patients with otorhinolaryngological infections -Efficacy, Safety and Tissue Penetration-
Jpn. J. Chemother. 68 (S-1): 81-95, 2020
Population pharmacokinetics and pharmacodynamics of oral lascufloxacin in patients with respiratory tract and otorhinolaryngological infections
Jpn. J. Chemother. 68 (S-1): 96-108, 2020